TIM-3-Next Generation Immunotherapy Market
TIM-3-Next Generation Immunotherapy Market is anticipated to be USD 1,218 Million in the year 2035
Market Driver- Launch of potential upcoming therapies
TIM-3-Next Generation Immunotherapy Pipeline
Emerging Therapies
And many others
Key Players:-
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary
3. Competitive Intensity of TIM-3-Next Generation Immunotherapy
4. Market Competition of TIM-3-Next Generation Immunotherapy
5. Technological innovations in TIM-3-Next Generation Immunotherapy
6. Multivariate analysis of the key players in TIM-3-Next Generation Immunotherapy
7. TIM-3-Next Generation Immunotherapy Market Overview at a Glance
7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035
8. Pipeline Therapeutics Analysis (Active Products)
9. Overview: Next Generation Immunotherapy
9.1. Immune Checkpoint Inhibitors
9.2. TIM-3
10. Future Prospects and Challenges in TIM-3-Next Generation Immunotherapy
10.1. Current Clinical Challenges in Immunotherapies
10.2. Future direction of improving response rates of Immunotherapy
11. SWOT Analysis
12. Epidemiology and Forecasting Assumptions
13. Emerging Drugs
13.1. Target indications of TIM-3
13.2. TSR-022: GlaxoSmithKline
13.2.1. Drug Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Product Profile
13.3. MBG453: Novartis
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Product Profile
13.4. ONO-7807/BMS-986258: Bristol-Myers Squibb/ Ono Pharmaceuticals
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Product Profile
13.5. BGB-A425 +/– Tislelizumab: BeiGene
13.5.1. Drug Description
13.5.2. Clinical Development
13.5.3. Product Profile
13.6. INCAGN2390: Incyte Biosciences/Agenus
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Product Profile
13.7. Sym023: Symphogen
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Product Profile
13.8. RG7769/RO7121661: Roche
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Product Profile
13.9. LY3321367: Eli Lilly
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Product Profile
13.10. Sym022: Symphogen
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Product Profile
14. Assessment by Indication
15. Assessment by Route of Administration
16. Assessment by Stage and Indication
17. Assessment by stage and Route of Administration
18. TIM-3-7 Major Market Analysis
18.1. Market Outlook in the 7MM
18.1.1. Total Market size of TIM-3 in 7MM
18.1.2. Market Size of TIM-3 by indication in 7MM
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/